Overview

ORYZON is a publicly listed, clinical-stage biopharmaceutical company and a European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches for disorders of the central nervous system (CNS), as well as oncology and hematology.

ORYZON has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since its listing, the company has attracted specialized investors from the United States, Europe, and Israel through several PIPEs led by U.S. investment banks.

The company has a broad pipeline, with two compounds in clinical development: vafidemstat (also known as ORY-2001), a CNS-optimized LSD1 inhibitor advancing as a Phase III-ready asset for neurological and psychiatric disorders, and iadademstat (also known as ORY-1001), a highly potent and selective LSD1 inhibitor in Phase Ib and II clinical trials in oncology and hematology, which has been granted orphan-drug status by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Oryzon’s pipeline also includes ORY-4001, a highly selective HDAC6 inhibitor for the treatment of neurological disorders such as amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth disease (CMT), as well as additional programs at earlier stages of development.

Oryzon’s portfolio of epigenetic drug candidates has been created internally from a concerted effort of its functional genomics, medicinal chemistry, preclinical, and clinical development teams. The company has a strong intellectual property (IP) position and is the originator and owner of all its IP portfolio.

The company is supported by an experienced management team, an international Board of Directors, and world-renowned clinical, regulatory, and industry experts.

ORYZON has offices in Spain and the United States.